≥
nstructed to read the ‘Instructions for use’ provided in the package leaflet before administration.
syringe, that is to say, essentially ‘sodium free’.
essentially ‘sodium free’.
psoriasis to 15.6% in Crohn’s disease)
organ class and are based on the following convention: very common (≥ 1/10); common (≥
1/10); uncommon (≥
1/100); rare (≥
There is limited safety information in subjects aged ≥65 years.
psoriasis who had a body surface area (BSA) involvement of ≥10%, a static Physician Global 
Assessment (sPGA) score of ≥3 in the overall assessment (plaque thickness/induration, erythema, and
≥12, and who were candidates for systemic therapy or phototherapy.
Examination of age, gender, race, body weight ≤130 kg, baseline PASI score, concurrent psoriatic 
•
•
•
tender joints and ≥
subjects had ≥
rs at baseline, ≥
controlled p≤0.001 risankizumab vs placebo comparison.
p≤0.001 risankizumab vs placebo comparison.
nominal p≤0.05 risankizumab vs placebo comparison.
○ Placebo (N=481)   ──■──  Risankizumab (N=483)
point Physician’s Global Assessment of Fingernail 
F clear/minimal and ≥2
controlled p≤0.001 risankizumab vs placebo comparison.
score of ‘Mild’, ‘Moderate’ or ‘Severe’ at Baseline (Placebo N=190; risankizumab 
Nominal p≤0.001 risankizumab vs placebo comparison.
≤
≤0.001))
≤0.001))
≥
d efficacy of Skyrizi for the treatment of Crohn’s disease in 
‘sodium free’.
Crohn’s disease
1/10); uncommon (≥
1/100); rare (≥
following convention: very common (≥ 1/10); common (≥
Crohn’s disease
profile observed in patients with Crohn’s disease treated with risankizumab was 
For subjects with Crohn’s disease treated with risankizumab at the recommended 
There is limited safety information in subjects aged ≥65 years.
In a Phase 2 study of subjects with Crohn’s disease, expression of genes associated with the IL
in Phase 3 induction studies in Crohn’s patients. Decreases in FCP, CRP and serum IL
active Crohn’s disease in three multicentre, randomised, double
of 220 to 450, an average daily stool frequency (SF) ≥4 and/or average daily abdominal pain score 
(APS) ≥2, and a Simple Endoscopic Score for CD (SES CD) of ≥6, or ≥4 for isolated ileal disease, 
age or older with a Crohn’s Disease Activity Index (CDAI) 
included a 12 week extension period for subjects who did not achieve SF/APS clinical response (≥ 
rease in SF and/or ≥ 30% decrease in APS and both not worse than baseline) at 
(p≤0.01).
Nominal p ≤ 0.0
average daily AP score ≤1 and not worse than baseline.
: average daily SF ≤2.8 and n
Enhanced SF/APS clinical response: ≥60% decrease in average daily SF and/or ≥35% decrease in 
CD ≤4 and at least a 2
≥
=3%, placebo=11%, p≤0.01).
(p≤0.01). 
Nominal p≤0.01 
Nominal p≤0.05 
p≤0.01). 
p≤ 0.01).
paediatric population in the treatment of Crohn’s disease 
In subjects with Crohn’s dis
with Crohn’s disease, V
with Crohn’s disease, CL was 0.30
healthy subjects or subjects with psoriasis or Crohn’s disease.
pharmacokinetic analyses in Crohn’s disease.
Crohn’s disease exposed to risankizumab, 
old subjects with Crohn’s disease were similar 
Crohn’s disease exposed to 
meaningful impact on risankizumab clearance in subjects with psoriasis, or Crohn’s disease.
with plaque psoriasis or Crohn’s disease. No clinically meaningful differences in risankizumab 
≥
The safety and efficacy of Skyrizi for the treatment of Crohn’s disease in 
nstructed to read the ‘Instructions for use’ provided in the package leaflet 
essentially ‘sodium free’.
essentially ‘sodium free’.
psoriasis to 15.6% in Crohn’s disease
organ class and are based on the following convention: very common (≥ 1/10); common (≥
1/10); uncommon (≥
1/100); rare (≥
Crohn’s disease
patients with Crohn’s disease treated with risankizumab was 
For subjects with Crohn’s disease treated with risankizumab at the recommended 
There is limited safety information in subjects aged ≥65
In a Phase 2 study of subjects with Crohn’s disease, expression of genes associated with the IL
in Phase 3 induction studies in Crohn’s patients. Decreases in FCP, CRP and 
active Crohn’s disease in three multicentre, randomised, double
studies. Enrolled subjects were 16 years of age or older with a Crohn’s Disease Activity Index (CDAI) 
of 220 to 450, an average daily stool frequency (SF) ≥4 and/or average daily abdominal pain score 
CD) of ≥6, or ≥4 for isolated ileal disease, 
(APS) ≥2, and a Simple E
30% decrease in SF and/or ≥ 30% decrease in APS and both not worse than baseline) 
period for subjects who did not achieve SF/APS clinical response (≥ 
(p≤0.01).
Nominal p ≤ 0.0
Clinical remission based on SF/APS: average daily SF ≤2.8 and not worse than baseline and 
average daily AP score ≤1 and not worse than baseline.
Enhanced SF/APS clinical response: ≥60% decrease in average daily SF and/or ≥35% decrease in 
CD ≤4 and at least a 2
≥
=3%, placebo=11%, p≤0.01).
(p≤0.01). 
Nominal p≤0.01 
Nominal p≤0.05 
p≤ 0.01).
≤0.01)
risankizumab in one or more subsets of the paediatric population in the treatment of Crohn’s disease 
In subjects with Crohn’s disease treated with 600
with Crohn’s disease, V
with Crohn’s disea
healthy subjects or subjects with psoriasis or Crohn’s disease.
pharmacokinetic analyses in Crohn’s disease.
574 subjects with Crohn’s disease exposed to risankizumab, 
old subjects with Crohn’s disease were 
574 subjects with Crohn’s disease exposed to 
iasis, or Crohn’s disease.
with plaque psoriasis or Crohn’s disease. No clinically meaningful differences in risankizuma
•
•
•
–
–
–
–
–
–
–
•
•
medicine works by stopping a protein in the body called ‘IL 23’, which causes inflammation.
•
•
•
•
•
packaging after “Lot”) and keep this information in a safe place.
•
•
•
•
•
‘sodium free’.
This medicine is given as an injection under your skin (called a ‘subcutaneous injection’).  
Read section 7 ‘Instructions for use’ at the end of this leaflet before injecting Skyrizi yourself.
•
•
•
•
•
•
•
•
•
•
•
•
‘EXP’.
България
АбВи ЕООД
Тел: +359 2 90 30 430
Česká republika
Ελλάδα
AbbVie ΦΑΡΜΑΚΕΥΤΙΚΗ Α.Ε.
Τηλ: +30 214 4165 555
Κύπρος
AbbVie Biofarmacevtska družba d.o.o.
Τηλ: +357 22 34 74 40
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
First “click”             15 seconds
•
Second “click”
• A loud “click” means the start of the 
• the pen has made a second “click” 
•
needle tip and make another “click.” 
•
•
•
•
•
•
This medicine works by stopping a protein in the body called ‘IL 23’, which causes inflammation. 
•
•
•
•
•
packaging after “Lot”) and keep this information in a safe place.
•
•
•
•
•
essentially ‘sodium free’.
This medicine is given as an injection under your skin (called a ‘subcutaneous injection’).  
Read section 7 ‘Instructions for use’ at the end of this leaflet before injecting Skyrizi yourself.
•
•
•
•
•
•
•
•
•
•
•
•
after ‘EXP’.
България
АбВи ЕООД
Тел: +359 2 90 30 430
Česká republika
Ελλάδα
ΦΑΡΜΑΚΕΥΤΙΚΗ Α.Ε.
Τηλ: +30 214 4165 555
AbbVie Biofarmacevtska družba d.o.o.
Κύπρος
Τηλ: +357 22 34 74 40
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
called ‘IL 23’, which causes inflammation.
•
•
•
•
•
packaging after “Lot”) and keep this information in a safe place.
•
•
•
‘sodium free’.
This medicine is given as 2 injections under your skin (called ‘subcutaneous injections’).  
Read section 7 ‘Instructions for use’ at the end of this leaflet before injecting Skyrizi yourself.
•
•
•
•
•
•
•
•
•
•
•
•
after ‘EXP’.
България
АбВи ЕООД
Тел:+359 2 90 30 430
Česká republika
Ελλάδα
AbbVie ΦΑΡΜΑΚΕΥΤΙΚΗ Α.Ε.
Τηλ:
AbbVie Biofarmacevtska družba d.o.o.
Κύπρος
Τηλ: +357 22 34 74 40
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
patients with moderate to severe Crohn’s disease.
This medicine works by stopping a protein in the body called ‘IL 23’, which causes inflammation.
Crohn’s disease is an inflammatory disease of the digestive tract. If you have active Crohn’s disease 
Skyrizi to treat your Crohn’s disease.
•
•
•
•
•
number (which is on the packaging after “Lot”).
•
•
•
•
•
free’.
‘sodium
•
•
•
•
•
•
•
•
•
•
•
•
‘EXP’.
България
АбВи ЕООД
Тел: +359 2 90 30 430
Česká republika
Ελλάδα
AbbVie ΦΑΡΜΑΚΕΥΤΙΚΗ Α.Ε.
Τηλ: +30 214 4165 555
AbbVie Biofarmacevtska družba d.o.o.
Κύπρος
Τηλ: +357 22 34 74 40
moderate to severe Crohn’s disease.
This medicine works by stopping a protein in the body called ‘IL 23’, which causes inflammation.
Crohn’s disease is an inflammatory disease of the digestive tract. If you have active Crohn’s disease 
Skyrizi to treat your Crohn’s disease.
•
•
•
•
•
packaging after “Lot”) and keep this information in a safe place.
•
•
•
•
•
‘sodium free’.
This medicine is given as an injection under your skin (called a ‘subcutaneous injection’).
Read section 7 ‘Instructions for use’ at the end of this leaflet before injecting Skyrizi yourself.
•
•
•
•
•
•
•
•
•
•
•
•
after ‘EXP’.
България
АбВи ЕООД
Тел: +359 2 90 30 430
Česká republika
Ελλάδα
AbbVie ΦΑΡΜΑΚΕΥΤΙΚΗ Α.Ε.
Τηλ: +30 214 4165 555
AbbVie Biofarmacevtska družba d.o.o.
Κύπρος
Τηλ: +357 22 34 74 40
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
discover missing pieces, or if it’s damaged
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
“click”
“click”
“snap”
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
“click”
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
patients with moderate to severe Crohn’s disease.
This medicine works by stopping a protein in the body called ‘IL 23’, which causes inflammation.
Crohn’s disease is an inflammatory disease of the digestive tract. If you have active Crohn’s disease 
Skyrizi to treat your Crohn’s disease.
•
•
•
•
•
number (which is on the packaging after “Lot”).
•
•
•
•
•
‘sodium free’.
an injection under your skin (called a ‘subcutaneous injection’) 
•
•
•
•
•
•
•
•
•
•
•
•
after ‘EXP’.
България
АбВи ЕООД
Тел: +359 2 90 30 430
Česká republika
Ελλάδα
ΦΑΡΜΑΚΕΥΤΙΚΗ Α.Ε.
Τηλ: +30 214 4165 555
Biofarmacevtska družba d.o.o.
Κύπρος
Τηλ: +357 22 34 74 40
STEP 1
STEP 2
Injectable areas
•
•
•
•
•
•
•
•
STEP 3
      Check liquid
STEP 4
•
•
•
•
•
•
•
•
•
STEP 5
STEP 6
•
STEP 7
